COMPANY PROFILE // THE 014 REPORT
UroGen Pharma Ltd.
URGN (Nasdaq)
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
UroGen Pharma Ltd. is an SEC-registered operating company in pharmaceutical preparations, based in Ra'Anana; listed as URGN (Nasdaq).[source] It reported revenue of $109.8 million for the fiscal year ended 2025-12-31.[source] It has filed 60 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-13.[source] Its largest institutional holders on 13F filings are RTW INVESTMENTS, LP, BlackRock, Inc., Kynam Capital Management, LP (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- RTW INVESTMENTS, LP$167.2M
- BlackRock, Inc.$117.8M
- Kynam Capital Management, LP$89.6M
- Jefferies Financial Group Inc.$80.9M
- AMERICAN CENTURY COMPANIES INC$62.0M
- ACORN CAPITAL ADVISORS, LLC$61.6M
- Point72 Asset Management, L.P.$56.1M
- FRONTIER CAPITAL MANAGEMENT CO LLC$55.5M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Barrett Elizabeth A. · Chief Executive Officer (Officer) · latest Form 4 2026-02-19 · filing · LinkedIn search
- Degnan Chris · Chief Financial Officer (Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Schoenberg Mark · Chief Medical Officer (Officer) · latest Form 4 2026-02-04 · filing · LinkedIn search
- Smith Jason Drew · General Counsel (Officer) · latest Form 4 2026-02-11 · filing · LinkedIn search
- BUTITTA CYNTHIA M · Director · latest Form 4 2025-12-01 · filing · LinkedIn search
- Belldegrun Arie · Director · latest Form 4 2025-08-27 · filing · LinkedIn search
- Holden Stuart · Director · latest Form 4 2025-12-01 · filing · LinkedIn search
- Robinson James A. Jr. · Director · latest Form 4 2026-02-27 · filing · LinkedIn search
- WEN LEANA · Director · latest Form 4 2025-12-01 · filing · LinkedIn search
- Wildman Daniel George · Director · latest Form 4 2025-12-01 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001668243 | source |
| EIN | 00-0000000 | source |
| NY DOS IDpossible match | 5132700 | record |
| Business address (SEC) | 9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007 | source |
Does not exist in the records we hold: LEI, UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Allogene Therapeutics, Inc. · Barrett Elizabeth A.
- Autolus Therapeutics plc · BUTITTA CYNTHIA M
- Olema Oncology, Inc. · BUTITTA CYNTHIA M
- Century Therapeutics, Inc. · BUTITTA CYNTHIA M
- Allogene Therapeutics, Inc. · Belldegrun Arie
- Eledon Pharmaceuticals, Inc. · Robinson James A. Jr.
- GLAUKOS Corp · WEN LEANA
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-04 filing S-8 · SEC EDGAR
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-09 filing 144 · SEC EDGAR
- 2026-09-09 filing 144 · SEC EDGAR
- 2026-09-09 filing 144 · SEC EDGAR
- 2026-08-20 filing 144 · SEC EDGAR
- 2026-08-20 filing 8-K items 8.01 · SEC EDGAR
- 2026-08-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-09 filing 144 · SEC EDGAR
- 2026-06-23 officer change 8-K items 3.03,5.02,5.07,9.01 · SEC EDGAR
- 2026-06-22 filing 144 · SEC EDGAR
- 2026-06-09 filing 144 · SEC EDGAR
- 2026-06-02 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-27 filing ARS · SEC EDGAR
- 2026-05-08 filing 144 · SEC EDGAR
- 2026-05-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-17 filing PRE 14A · SEC EDGAR
- 2026-03-02 filing Annual report (10-K) · SEC EDGAR
- 2026-03-02 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-02 filing 8-K items 1.01,2.03 · SEC EDGAR
- 2026-02-03 filing 144 · SEC EDGAR
- 2025-11-19 filing 144 · SEC EDGAR
- 2025-11-06 filing S-8 · SEC EDGAR
- 2025-11-06 filing S-3ASR · SEC EDGAR
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-06 filing 8-K items 2.02,9.01 · SEC EDGAR
147 earlier entries
- 2025-10-09 insider First Form 3/4/5 on record for Degnan Chris (Chief Financial Officer)
- 2025-09-09 filing 144
- 2025-09-09 filing 144
- 2025-08-27 officer change 8-K items 5.02,5.07,9.01
- 2025-08-27 insider First Form 3/4/5 on record for BUTITTA CYNTHIA M (Director)
- 2025-08-27 insider First Form 3/4/5 on record for Belldegrun Arie (Director)
- 2025-08-27 insider First Form 3/4/5 on record for Holden Stuart (Director)
- 2025-08-27 insider First Form 3/4/5 on record for Robinson James A. Jr. (Director)
- 2025-08-27 insider First Form 3/4/5 on record for WEN LEANA (Director)
- 2025-08-27 insider First Form 3/4/5 on record for Wildman Daniel George (Director)
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-07-30 insider First Form 3/4/5 on record for Barrett Elizabeth A. (Chief Executive Officer)
- 2025-07-30 insider First Form 3/4/5 on record for Smith Jason Drew (General Counsel)
- 2025-07-29 filing 144
- 2025-07-29 filing 144
- 2025-07-16 filing ARS
- 2025-07-15 filing Proxy statement
- 2025-07-03 officer change 8-K items 5.02
- 2025-06-13 filing 8-K items 8.01
- 2025-06-11 insider First Form 3/4/5 on record for Schoenberg Mark (Chief Medical Officer)
- 2025-06-10 filing 144
- 2025-06-09 filing SCHEDULE 13D/A
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-04-30 filing 10-K/A
- 2025-03-10 filing Annual report (10-K)
- 2025-03-10 filing 8-K items 2.02,9.01
- 2025-02-20 filing 8-K items 1.01,3.02
- 2025-01-14 filing 8-K items 7.01,9.01
- 2024-11-18 filing SC 13D/A
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02,9.01
- 2024-10-09 officer change 8-K items 5.02,9.01
- 2024-09-24 filing 8-K items 2.03
- 2024-09-13 officer change 8-K items 5.02
- 2024-09-10 filing 144
- 2024-08-15 filing 8-K items 8.01
- 2024-08-13 filing S-8
- 2024-08-13 filing Quarterly report (10-Q)
- 2024-08-13 filing 8-K items 2.02,9.01
- 2024-08-08 officer change 8-K items 5.02,5.07,9.01
- 2024-07-09 filing ARS
- 2024-07-01 filing DEFA14A
- 2024-07-01 filing Proxy statement
- 2024-06-18 filing 8-K items 1.01,8.01,9.01
- 2024-06-18 filing 424B5
- 2024-06-17 filing 424B5
- 2024-06-13 filing 8-K items 7.01,8.01,9.01
- 2024-06-11 filing 144
- 2024-05-13 filing Quarterly report (10-Q)
- 2024-05-13 filing 8-K items 2.02,9.01
- 2024-04-29 filing 10-K/A
- 2024-03-18 filing 144
- 2024-03-14 filing Annual report (10-K)
- 2024-03-14 filing 8-K items 2.02,9.01
- 2024-03-04 filing 8-K items 7.01,9.01
- 2024-03-01 filing 8-K items 7.01
- 2024-02-22 filing SC 13D/A
- 2024-02-07 filing 8-K items 7.01,9.01
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-01-17 filing 8-K items 1.01,8.01
- 2024-01-02 filing 8-K items 1.01
- 2023-12-05 filing UPLOAD
- 2023-11-27 filing CORRESP
- 2023-11-16 filing UPLOAD
- 2023-11-14 filing S-8
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-11-14 filing 8-K items 2.02,9.01
- 2023-09-15 filing EFFECT
- 2023-09-13 filing CORRESP
- 2023-09-12 filing UPLOAD
- 2023-09-11 officer change 8-K items 5.02,5.07
- 2023-09-08 filing S-3
- 2023-08-14 filing D
- 2023-08-10 filing Quarterly report (10-Q)
- 2023-08-10 filing 8-K items 2.02,9.01
- 2023-08-04 filing SC 13D
- 2023-08-01 filing ARS
- 2023-08-01 filing DEFA14A
- 2023-08-01 filing Proxy statement
- 2023-07-27 filing 8-K items 1.01,3.02,7.01,8.01,9.01
- 2023-07-25 officer change 8-K items 5.02
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-01 filing 10-K/A
- 2023-03-24 filing Annual report (10-K)
- 2023-03-22 filing 8-K items 2.02,9.01
- 2022-12-01 filing 424B5
- 2022-11-29 filing EFFECT
- 2022-11-23 filing CORRESP
- 2022-11-22 filing UPLOAD
- 2022-11-16 filing S-3/A
- 2022-11-15 filing S-3
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-11-09 officer change 8-K items 5.02
- 2022-10-21 filing 8-K items 2.03
- 2022-09-12 officer change 8-K items 5.02
- 2022-08-11 filing Quarterly report (10-Q)
- 2022-08-11 filing S-8
- 2022-08-11 filing 8-K items 2.02,9.01
- 2022-06-13 officer change 8-K items 5.02,5.07,9.01
- 2022-05-17 filing DEFA14A
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-02 filing DEFA14A
- 2022-05-02 filing Proxy statement
- 2022-03-21 filing S-8
- 2022-03-21 officer change 8-K items 2.02,5.02,9.01
- 2022-03-21 filing Annual report (10-K)
- 2022-03-08 filing 8-K items 1.01,2.03
- 2021-11-15 filing 8-K items 1.02,2.02,9.01
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-11-10 filing 8-K items 8.01
- 2021-09-13 filing 8-K items 8.01
- 2021-08-05 filing S-8
- 2021-08-04 filing 8-K items 2.02,9.01
- 2021-08-04 filing Quarterly report (10-Q)
- 2021-07-14 filing 8-K items 2.02,8.01,9.01
- 2021-06-08 officer change 8-K items 5.02,5.07,9.01
- 2021-05-13 filing 8-K items 2.02,9.01
- 2021-05-13 filing Quarterly report (10-Q)
- 2021-04-28 filing DEFA14A
- 2021-04-28 filing Proxy statement
- 2021-03-18 filing 8-K items 2.02,9.01
- 2021-03-18 filing 8-K items 1.01,7.01,9.01
- 2021-03-18 filing Annual report (10-K)
- 2021-01-13 filing 8-K items 8.01,9.01
- 2021-01-11 filing 8-K items 7.01,9.01
- 2020-12-03 filing 8-K items 8.01,9.01
- 2020-11-17 filing 8-K items 8.01,9.01
- 2020-11-09 filing 8-K items 2.02,9.01
- 2020-11-09 filing Quarterly report (10-Q)
- 2020-09-09 officer change 8-K items 5.02,9.01
- 2020-08-27 filing 8-K items 8.01,9.01
- 2020-08-10 filing S-8
- 2020-08-10 filing Quarterly report (10-Q)
- 2020-08-10 filing 8-K items 2.02,9.01
- 2020-06-10 officer change 8-K items 4.01,5.02,5.07,9.01
- 2020-05-15 filing 8-K items 8.01,9.01
- 2020-05-07 filing Quarterly report (10-Q)
- 2020-04-29 filing DEFA14A
- 2020-04-29 filing Proxy statement
- 2020-04-16 filing 8-K items 8.01,9.01
- 2020-03-23 officer change 8-K items 5.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) S-8 filed (FORM S-8)
- 2026-11-04 (within 30 days) 10-Q filed (FORM 10-Q)
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-20 (older) 8-K filed: Item 8.01 other event
- 2026-08-05 (older) 10-Q filed (FORM 10-Q)
- 2026-08-05 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-23 (older) 8-K filed: Item 3.03 rights of holders modified; Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-02 (older) 8-K filed: Item 8.01 other event
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:URGN The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1668243 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | URGN / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | M96088105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001668243 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $109,788,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 08:34 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$153,494,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 08:34 UTC | Report an error |
| Total assets (at 2025-12-31) | $200,455,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 08:34 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$105,474,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 08:34 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $110,745,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 08:34 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
| State of incorporation | L3 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
| Business address | 9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 08:34 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$162,444,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 08:34 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $289,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 08:34 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $125,000,000 | 2025-12-31 | 10-K, XBRL LongTermDebt | as filed | 2026-11-20 08:34 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $3,127,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 08:34 UTC | Report an error |
| Form D total offering amount (D filed 2023-08-14) | $120,000,000 | 2023-08-14 | D | as filed | 2026-11-20 08:34 UTC | Report an error |
| Form D total amount sold (D filed 2023-08-14) | $120,000,000 | 2023-08-14 | D | as filed | 2026-11-20 08:34 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2023-08-14 | D | as filed | 2026-11-20 08:34 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2023-08-14 | D | as filed | 2026-11-20 08:34 UTC | Report an error |
| Form D date of first sale | 2023-07-26 | 2023-08-14 | D | as filed | 2026-11-20 08:34 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001437749-26-034780
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $89,001,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Net income (loss) | -$1,462,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Cash and cash equivalents | $85,564,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Debt due in the next 12 months | $0 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Debt due in year 2 | $0 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Debt due in year 3 | $0 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Debt due in year 4 | $150,000,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
| Debt due in year 5 | $50,000,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001437749-26-034780 | 2026-11-20 08:34 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing S-8 filed (FORM S-8)
- 2026-11-04 Filing 10-Q filed (FORM 10-Q)
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-20 Filing 8-K filed: Item 8.01 other event
- 2026-08-05 Filing 10-Q filed (FORM 10-Q)
- 2026-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-23 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-02 Filing 8-K filed: Item 8.01 other event
- 2026-05-27 Filing ARS filed (FORM ARS)
- 2026-05-06 Filing 10-Q filed (FORM 10-Q)
- 2026-05-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing DEF 14A filed (FORM DEF 14A)
- 2026-04-17 Filing PRE 14A filed (FORM PRE 14A)
- 2026-03-02 Filing 10-K filed (FORM 10-K)
- 2026-03-02 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-02 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation
- 2025-11-06 Filing S-8 filed
- 2025-11-06 Filing S-3ASR filed
- 2025-11-06 Filing 10-Q filed (FORM 10-Q)
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-27 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q filed (FORM 10-Q)
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-07-16 Filing ARS filed (ANNUAL REPORT)
- 2025-07-15 Filing DEF 14A filed (FORM DEF 14A)
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02
Results of Operations and Financial Condition On November 4, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be… the 8-K · retrieved 2026-11-20 08:34 UTC - 2026-08-20 8-K Item 8.01, Other Events
On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option Agreement”) with IntraGel Therapeutics, Ltd. (“IntraGel”), a company organized under the laws of Israel. Pursuant to the Option Agreement, UroGen U.S. obtained from IntraGel (i) an exclusive option to obtain an exclusive, worldwide license under certain intellectual property rights of IntraGel to develop, commercialize and exploit IntraGel’s TumoCure product formulated with IntraGel’s proprietary, biodegradable hydrogel sustained-release delivery platform (collectively, “SRGel platform”) for the… the 8-K · retrieved 2026-11-20 08:34 UTC - 2026-08-05 8-K Item 2.02
Results of Operations and Financial Condition On August 5, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set… the 8-K · retrieved 2026-11-20 08:34 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | $167,215,336 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 2 | BlackRock, Inc. | $117,813,765 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 3 | Kynam Capital Management, LP | $89,578,818 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 4 | Jefferies Financial Group Inc. | $80,947,194 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 5 | AMERICAN CENTURY COMPANIES INC | $62,034,564 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 6 | ACORN CAPITAL ADVISORS, LLC | $61,581,856 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 7 | Point72 Asset Management, L.P. | $56,140,203 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 8 | FRONTIER CAPITAL MANAGEMENT CO LLC | $55,514,521 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 9 | Opaleye Management Inc. | $52,991,853 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | $47,912,827 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:34 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
4 state and city records carry this company's exact name, from 3 sources. Possible matches only.
State licences (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchUROGEN PHARMA · name equals 'Urogen Pharma' but other unrelated entities share it · sx:elic:ctcred:2534638 Compare
- possible matchUroGen Pharma Inc. · name equals 'Urogen Pharma' but other unrelated entities share it · sx:elic:ctcred:1676648 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchUroGen Pharma Ltd. · exact legal name · sx:ctgov:h7dbd05f315846401 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchUROGEN PHARMA, INC. · name equals 'Urogen Pharma' but other unrelated entities share it · sx:nydos:5132700 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1668243.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001668243. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.